Since Gaining European Authority Approval for Victrelis in July and Incivo in September, Protease Inhibitor Share Has Penetrated Nearly One-Third of the Genotype 1 Market

Since Gaining European Authority Approval for Victrelis in July and Incivo in September, Protease Inhibitor Share Has Penetrated Nearly One-Third of the Genotype 1 Market and is Anticipated to Significantly Increase Over the Next Six Months

BioTrends Research Group Posted on:21 May 12

BioTrends Research Group, one of the world’s leading research and advisory firms for specialized biopharmaceutical issues, finds that Vertex and Janssen / Tibotec’s Incivo (telaprevir) and Merck / Roche’s Victrelis (boceprevir) are quickly being adopted as the new standard of care in genotype 1 hepatitis C (HCV) patients in the EU5. Since their European launch, the protease inhibitors (PIs) have penetrated approximately one-third of the genotype 1 hepatitis C (HCV) market, however surveyed physicians anticipate that PI share will account for over half of this market in the next six months. Currently, Incivo makes up 5 percent more of the EU5 protease inhibitor market than Victrelis, though share for each is expected to significantly increase in the future, according to the recently released TreatmentTrends®: Hepatitis C (EU)report.

Furthermore, the 186 gastroenterologists and 69 hepatologists included in the survey are significantly more satisfied with, and view Incivo as performing significantly better than all other HCV treatments, including Victrelis. Specifically, physicians perceive Incivo as significantly outperforming Victrelis on the top three most important attributes for HCV treatments: ‘efficacy in genotype 1 patients,’ ‘efficacy in prior non-responders and partial responders,’ and ‘efficacy in treatment naïve patients.’

Though the majority of surveyed physicians agree that the PIs, Incivo and Victrelis, are important advances for the treatment of HCV, they also agree that there is a need for alternative therapies in the treatment and management of HCV. Moreover, physicians report that nearly one-third of their genotype 1 HCV patients, and slightly over one-quarter of their genotype 2/3 patients, are actively delaying treatment to wait for interferon-free regimens to become available.

With regard to products in development, surveyed physicians report the greatest interest with Gilead’s GS-7977, followed closely by Bristol-Myers Squibb’s daclatasvir. However, GS-7977 and Tibotec / Medivir’s TMC-435 are anticipated to bring the most value to practices for the treatment of HCV, primarily due to GS-7977’s efficacy in trials, pan-genotype usage and mechanism of action, and TMC-435’s efficacy and ease of administration.

Specific analysis of Incivek (Incivo) and Victrelis at one-year post U.S. launch is available via the LaunchTrends®: Incivek and Victrelis, Wave 4 report, publishing at the end of May 2012. Additional analysis of the U.S. hepatitis C market will be covered in TreatmentTrends: Hepatitis C in the U.S., a two-wave report series publishing in June and November 2012.

TreatmentTrends: Hepatitis C (EU) is a syndicated annual report that examines current trends in the management of hepatitis C from the perspective of gastroenterologists and hepatologists with a focus on analyzing their attitudes, perceptions and self-reported prescribing behavior. In addition, this report provides insight into the practice patterns, and current and projected use of various products. TreatmentTrends® also evaluates perceived product advantages and disadvantages, as well as sales and messaging efforts of key market players. This study was fielded with a total of 186 gastroenterologists and 69 hepatologists across France, Germany, Spain, Italy and the United Kingdom via an online survey.

About BioTrends Research Group

BioTrends Research Group provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact us at (610) 321-9400 or www.bio-trends.com.

About Decision Resources Group

Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

Business Wire
http://www.businesswire.com/

Last updated on: 21/05/2012 14:00:01

Source